3rd Quarter - Termination Amendment — OSIRIS THERAPEUTICS for OSIRIS THERAPEUTICS (2015)

Firm

OSIRIS THERAPEUTICS

Client

OSIRIS THERAPEUTICS

Income

—

Expenses

$50,000

Expense method

A: Lobbying Disclosure Act definitions

Terminated

Sep 30, 2015

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Issues related to reimbursement policy for Medicare products.

Lobbyist	Covered position, as disclosed
THERESA KATHLEEN DIXON	—

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Homeland Security, Dept of (DHS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.